Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (BFORE Trial): 24-month efficacy update and results by 3-month BCR-ABL1 transcript levels Meeting Abstract

  


Authors: Gambacorti-Passerini, C.; Brummendorf, T. H.; Abruzzese, E.; Rambaldi, A.; Ciceri, F.; Martino, B.; Hochhaus, A.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Kota, V.; Lipton, J. H.; Crescenzo, R. J.; Leip, E.; Viqueira, A.; Bardy-Bouxin, N.; Cortes, J. E.
Abstract Title: Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (BFORE Trial): 24-month efficacy update and results by 3-month BCR-ABL1 transcript levels
Meeting Title: 15th Congress of the Italian Society of Experimental Hematology
Journal Title: Haematologica
Volume: 103
Issue: Suppl. 3
Meeting Dates: 2018 Oct 18-20
Meeting Location: Rimini, Italy
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2018-10-01
Start Page: S96
End Page: S97
Language: English
ACCESSION: WOS:000451725500174
PROVIDER: wos
Notes: Meeting Abstract: PO060 -- Source: Wos